Skip to main content
Premium Trial:

Request an Annual Quote

Target Inks Prostate Assay Deal With Eastern Virginia Medical School

NEW YORK, March 21 (GenomeWeb News) - Target Discovery and the Virginia Prostate Center at Eastern Virginia Medical School are partnering to develop clinical assays to distinguish aggressive and non-aggressive prostate cancer, the company said today.


Terms of the agreement call for the Eastern Virginia Medical School to provide patient samples and mass spec analysis. Target will provide its mass defect technology and will integrate the biomarkers in its isonostics clinical platform.


Financial details were not provided.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.